Buy Wegovy subcutaneous solution in Saudi Arabia
Firstly, Buy Wegovy subcutaneous solution in Saudi Arabia 1.7 mg/0.75 mL (1.7 mg dose) Wegovy subcutaneous solution for 3 milliliters for sale in Saudi Arabia
- DOWNLOAD DRUG LABEL INFO: PDF XML
- MEDICATION GUIDE: HTML
- OFFICIAL LABEL (PRINTER FRIENDLY)
VIEW ALL SECTIONS
-
- HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use WEGOVY® safely and effectively. See full prescribing information for WEGOVY. WEGOVY (semaglutide) injection, for subcutaneous …
- TABLE OF CONTENTS
Table of Contents
- BOXED WARNING (WHAT IS THIS?)
WARNING: RISK OF THYROID C-CELL TUMORS
- •
- Secondly, In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether WEGOVY causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined [see Warnings and Precautions (5.1) and Nonclinical Toxicology (13.1)].
Wegovy subcutaneous solution for 3 milliliters for sale in Saudi Arabia
- •
- Lastly, WEGOVY is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Contraindications (4)]. Counsel patients regarding the potential risk for MTC with the use of WEGOVY and inform them of symptoms of thyroid tumors (e.g. a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treat with WEGOVY [see Contraindications (4) and Warnings and Precautions (5.1)]. buy wegovy subcutaneous solution in sweden/
- HIGHLIGHTS OF PRESCRIBING INFORMATION
-
- 1 INDICATIONS AND USAGE
WEGOVY is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in: • adults with an initial body mass index (BMI) of [see Dosage and …
- 2 DOSAGE AND ADMINISTRATION
2.1 Patient Selection – Adult Patients – Select adult patients for WEGOVY treatment as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management based …
- 3 DOSAGE FORMS AND STRENGTHS
Injection: clear, colorless solution available in 5 pre-filled, disposable, single-dose pens: • 0.25 mg/ 0.5mL – • 0.5 mg/ 0.5 mL – • 1 mg/ 0.5 mL – • 1.7 mg/ 0.75 mL – • 2.4 mg/ 0.75 mL
- 4 CONTRAINDICATIONS
WEGOVY is contraindicated in the following conditions: • A personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2 …
- 5 WARNINGS AND PRECAUTIONS
5.1 Risk of Thyroid C-Cell Tumors – In mice and rats, semaglutide caused a dose-dependent and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and …
- 6 ADVERSE REACTIONS
The following serious adverse reactions are described below or elsewhere in the prescribing information: • Risk of Thyroid C-Cell Tumors [see Warnings and Precautions (5.1)] • Acute Pancreatitis …
- 7 DRUG INTERACTIONS
7.1 Concomitant Use with an Insulin Secretagogue (e.g., Sulfonylurea) or Insulin – WEGOVY lowers blood glucose and can cause hypoglycemia. The risk of hypoglycemia is increased when WEGOVY is …
- 8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy – Pregnancy Exposure Registry – There will be a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to semaglutide during pregnancy. Pregnant women …
- 10 OVERDOSAGE
Overdoses have been reported with other GLP-1 receptor agonists. Effects have included severe nausea, severe vomiting, and severe hypoglycemia. In the event of overdose, appropriate supportive …
- 11 DESCRIPTION
WEGOVY (semaglutide) injection, for subcutaneous use, contains semaglutide, a human GLP-1 receptor agonist (or GLP-1 analog). The peptide backbone is produced by yeast fermentation. The main …
- 12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action – Semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1. Semaglutide acts as a GLP-1 receptor agonist that selectively binds to and activates the …
- 13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility – In a 2-year carcinogenicity study in CD-1 mice, subcutaneous doses of 0.3, 1 and 3 mg/kg/day (2-, 8-, and 22-fold the maximum …
- 14 CLINICAL STUDIES
14.1 Weight Management Studies in Adults with Overweight or Obesity – Overview of Clinical Studies in Adults – The safety and efficacy of WEGOVY for chronic weight management (weight loss and …
- 16 HOW SUPPLIED/STORAGE AND HANDLING
How Supplied – WEGOVY injection is a clear, colorless solution in a pre-filled, disposable, single-dose pen-injector with an integrated needle. It is supplied in cartons containing 4 pen-injectors …
- 17 PATIENT COUNSELING INFORMATION
Advise the patient to read the FDA-approved patient labeling (Medication Guide and Instructions for Use). Risk of Thyroid C-cell Tumors – Inform patients that semaglutide causes thyroid C-cell …
- MEDICATION GUIDE
WEGOVY® (wee-GOH-vee) (semaglutide) injection, for subcutaneous use – Read this Medication Guide and Instructions for Use before you start using WEGOVY and each time you get a refill. There may be …
- INSTRUCTIONS FOR USE
Instructions for Use – WEGOVY® (semaglutide) injection – WEGOVY comes in five strengths: Before you use your WEGOVY pen for the first time, talk to your healthcare provider or your …
- WEGOVY® 0.25 MG
NDC 0169-4525-14 List 452514 – 0.25 mg – wegovy® (semaglutide) injection – 0.25 mg/0.5 mL – Use Wegovy 1 time a week – 4 Single-Dose Prefilled Pens – Each pen delivers a single dose of …
- WEGOVY® 0.5 MG
NDC 0169-4505-14 List 450514 – 0.5 mg wegovy® (semaglutide) injection – 0.5 mg/0.5 mL – Use Wegovy 1 time a week – 4 Single-Dose Prefilled Pens – Each pen delivers a single dose of …
- WEGOVY® 1 MG
NDC 0169-4501-14 List 450114 – 1 mg wegovy® (semaglutide) injection – 1 mg/0.5 mL – Use Wegovy 1 time a week – 4 Single-Dose Prefilled Pens – Each pen delivers a single dose of 1 mg …
- WEGOVY® 1.7 MG
NDC 0169-4517-14 List 451714 – 1.7 mg wegovy® (semaglutide) injection – 1.7 mg/0.75 mL – Use Wegovy 1 time a week – 4 Single-Dose Prefilled Pens – Each pen delivers a single dose of …
- WEGOVY® 2.4 MG
NDC 0169-4524-14 List 452414 – 2.4 mg – wegovy® (semaglutide) injection – 2.4 mg/0.75 mL – Use Wegovy 1 time a week – 4 Single-Dose Prefilled Pens – Each pen delivers a single dose of … order yk 11 magnus in europe/
- 1 INDICATIONS AND USAGE
